四黄虎胶囊抗豚鼠生殖器疱疹病毒感染的实验研究

目的：探讨中药四黄虎胶囊治疗生殖器疱疹的作用机理。方法：将四黄虎胶囊用于治疗感染生殖器疱疹病毒的豚鼠模型，与阳性药物阿昔洛韦（ACV）对照，对豚鼠临床症状变化、体重、阴道分泌物病毒滴度等进行观测。结果：四黄虎各剂量组豚鼠阴道内病毒滴度与阿昔洛韦组比较差异无统计学意义（P〉0．05）；外阴症状评分四黄虎各剂量组均明显低于模型组，尤以四黄虎中剂量组最为明显，而且低于阿昔洛韦组；四黄虎对豚鼠体重变化有一定的保护作用。结论：中药四黄虎胶囊有较好抗生殖器疱疹病毒作用。     

抗病毒胶囊治疗初发性生殖器疱疹豚鼠模型实验研究

目的观察中药抗病毒胶囊治疗生殖器疱疹的豚鼠模型的效果和初步探讨其作用机理。方法先进行豚鼠生殖器疱疹造模,然后用中药抗病毒胶囊对生殖器疱疹豚鼠进行治疗,用外阴症状评分和阴道拭子病毒滴度进行疗效的评价和机理的探讨。结果中药抗病毒胶囊治疗生殖器疱疹豚鼠的疗效基本等同西药阿昔洛韦,其作用机理可能为抑制病毒的增殖和提高动物免疫功能而发挥疗效。结论抗病毒胶囊是治疗生殖器疱疹的有效药物。     

性病

不同期生殖器疱疹患外周血CD4^＋T细胞内细胞因子检测及临床意义，生殖器疱疹患免疫功能的观察研究，阿昔洛韦联合中药抗病毒颗粒治疗生殖器疱疹，泛昔洛韦与卡介菌素联合治疗复发性生殖器疱疹，中药黄白液对豚鼠生殖器疱疹复发感染模型的影响，     

豚鼠生殖器疱疹模型及细胞培养法观察中药抗病毒胶囊的抗病毒作用

目的 探讨病毒胶囊治疗生殖器疱疹的作用机理。方法 用雌性豚鼠生殖道单纯疱疹病毒（HSV）2型感染的模型,采取抗病毒胶囊内服,观察豚鼠阴道内病毒滴度、外阴症状;用体外细胞培养法观察抗病毒胶囊对HSV－2的直接灭活和三种给药途径下对HSV－2的抑制作用。结果 抗病毒胶囊组豚鼠阴道内病毒滴度与阿昔洛韦组比较差异无显著性（P＞0．05）;外阴症状评分在第2、3、5、7、8天显著低于生理盐水对照组（P＜0．05）,与阿昔洛韦组大致相同（P＞0．05）;细胞培养结果：抗病毒胶囊1号、2号对HSV－2的最低有效抑制浓度分别0．390625mg/ml和1．5625mg/mL。结论 中药抗病毒胶囊在动物体内和体外对HSV－2均有抑制作用。     

中药对复发性生殖器疱疹模型神经节的超微结构和潜伏病毒的影响

目的探讨中药抗病毒胶囊治疗复发性生殖器疱疹的作用机理。方法采用豚鼠阴道接种HSV-2,造成初发生殖器疱疹模型,然后给予中药抗病毒胶囊及西药阿昔洛韦治疗,愈后用环磷酰胺腹腔注射加紫外线局部照射方法诱导复发性豚鼠生殖器疱疹模型,取脊髓神经节用透射电镜观察豚鼠模型各组织的超微结构变化及采用定量PCR测定神经节的潜伏病毒量。结果抗病毒胶囊能有效减轻组织超微结构的变化和减少神经节潜伏病毒量。结论中药抗病毒胶囊在复发性生殖器疱疹动物模型体内有阻止HSV-2对神经节的感染和破坏作用。     

泛昔洛韦与阿昔洛韦治疗生殖器疱疹的临床对比观察

目的：评价泛昔洛韦治疗生殖器疱疹的疗效和安全性。方法：将150例病程在48小时以内的初发或复发性生殖器疱疹病例随机分配到泛昔洛韦治疗组和阿昔洛韦对照组中。在治疗后第7天复诊作临床评价，观察不良反应和部分患者治疗前后的血尿常规、血生化、心电图。结果：无论在初发病例还是在复发病例中，治疗组和对照组的痊愈时间、皮损愈合时间、自觉症状消失时间的差异均无显著性(P＞0．05)。两组病例的不良反应相似且轻微。结论：对生殖器疱疹，泛昔洛韦的疗效和安全性与阿昔洛韦相当，但使用较方便。     

阿昔洛韦联合阴道用乳杆菌胶囊治疗女性复发性生殖器疱疹的疗效分析

目的探讨阿昔洛韦联合阴道用乳杆菌胶囊治疗单纯疱疹病毒(HSV)感染引起的女性复发性生殖器疱疹患者的疗效和安全性。方法选取2016年10月至2018年10月四川省广安市人民医院诊治的220例复发性生殖器疱疹女性患者作为研究对象。按照随机数字表法分为观察组(n=110)和对照组(n=110)。观察组口服阿昔洛韦片联合阴道用乳杆菌胶囊,对照组仅口服阿昔洛韦片。观察并记录两组的皮损愈合时间、治疗效果、症候积分、不良反应及复发情况等指标。结果治疗后,观察组皮损愈合时间明显短于对照组,观察组总有效率明显高于对照组,差异具有统计学意义(P<0.05)。治疗后,观察组症候积分明显低于对照组,差异具有统计学意义(P<0.05)。治疗后第6个月、第12个月,观察组复发率明显低于对照组,差异具有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论阿昔洛韦联合阴道用乳杆菌胶囊治疗女性复发性生殖器疱疹的疗效确切,可缩短病程,降低复发率,且耐受性良好。     

阿昔洛韦致喉麻痹1例

患者女 ,2 7岁。因生殖器疱疹给予静脉滴注莪术油葡萄糖注射液 2 5 0ml(合肥第二制药厂生产 ,批号 0 10 90 70 2 2 ) ,阿昔洛韦 0 .2 5g(武汉生物化学制药厂生产 ,批号 2 0 0 110 80 5 )加生理盐水 2 5 0ml(四川科伦大药厂生产 ,批号A0 2 0 2 0 4.0 3 )治疗。莪术油葡萄糖液 60滴 /min ,阿昔洛韦液 80滴 /min。输完莪术油葡萄糖液后患者未感不适 ,当输入阿昔洛韦液 5min左右时患者突然喷嚏不止 ,咽喉发痒 ,干燥难忍 ,紧接声音嘶哑、失声 ,烦躁不安。体检 :急性痛苦面容 ,T 3 6.5℃ ,P 94次 /min ,R 2 4次 /min ,BP 16.5 /6.5kPa ,心率齐 …     

基因工程干扰素局部注射治疗生殖器疱疹32例

生殖器疱疹 (ＧＨ)主要是由单纯疱疹Ⅱ型病毒 (ＨＳＶ—Ⅱ )感染引起的生殖器及临近部位的水疱性炎性疾病[1 ] 。我科近年来采用深圳科兴生物制品有限公司生产的基因工程干扰素 (赛若金 )局部注射治疗男性生殖器疱疹 32例 ,取得较好疗效 ,现报告如下 :1　临床资料　 32例患者均为男性。年龄 2 0～ 45岁 ,平均30 2岁。病史 3天至 2年 ,平均 6个半月。其中初发 1 8例 ,复发 1 4例。发病时间 ,初发平均 4天 ,复发平均 2天 ,所有病均未发现合并其它性病。2　治疗方法　按就诊顺序分为Ａ　Ｂ两组。Ａ组 2 5例 ,口服无环鸟苷 0 2ｇ,每日 5次至皮…     

口服万乃洛韦治疗生殖器疱疹疗效观察

为了评价国产万乃洛韦 (伐昔洛韦 )治疗生殖器疱疹的疗效和安全性，我们于 1998年 9月至 1999年 4月以随机对照开放临床试验方法，对伐昔洛韦和阿昔洛韦治疗生殖器疱疹的疗效进行了观察，现报道如下。 一、资料和方法 1.入选标准：临床上有典型生殖器疱疹的症状和体征，确诊的初发或复发生殖器疱疹，病期在 48 h以内；年龄 18～ 60岁，男、女均可，近 2周内未内服或外用过抗病毒药物，愿意配合试验者。 2.治疗方法：伐昔洛韦组口服伐昔洛韦 (商品名丽珠威，丽珠制药厂生产 )，每日 2次，每次 0.3 g，连续 5 d。阿昔洛韦组口服阿昔洛韦 (…     

单纯疱疹病毒2型DNA疫苗对豚鼠抗病毒感染的研究

目的 探讨单纯疱疹病毒2型DNA疫苗的抗病毒感染效应.方法 重组DNA疫苗pcgD免疫雌性豚鼠,采用血清中和实验检测抗体,单纯疱疹病毒2型(HSV-2)sav株接种豚鼠,观察DNA疫苗保护动物抵抗HSV-2病毒感染的能力.结果 pc-gD免疫豚鼠产生的中和抗体效价远远高于对照组和生理盐水组,感染病毒后,表现出初发感染推迟,复发感染的严重程度下降.结论 DNA疫苗能有效地保护动物免受HSV-2病毒的攻击,延缓初发感染,减少复发感染.     

Risk factors for infection with herpes simplex virus type 2: role of smoking,douching, uncircumcised males,and vaginal flora

BACKGROUND: Herpes simplex virus type 2 (HSV-2), the primary cause of genital herpes, is one of the most prevalent sexually transmitted diseases worldwide. Epidemiologic serosurveys suggest that infections occur more frequently in women than in men. GOAL: The goal of the study was to identify unique correlates of HSV-2 infection in women that might contribute to their increased susceptibility of infection or suggest opportunities for decreasing the incidence of disease. STUDY DESIGN: We enrolled 1207 women aged 18 to 30 years from three Pittsburgh health clinics in a cross-sectional study. Each woman provided demographic and behavioral information, vaginal swab specimens for bacterial culture, a vaginal smear for Gram stain diagnosis of bacterial vaginosis, and blood for HSV-1 and HSV-2 serology. RESULTS: Black race, older age, cigarette smoking, douching, a greater number of lifetime sex partners, a history of intercourse with an uncircumcised partner, the presence of vaginal group B Streptococcus, and abnormal vaginal flora were among the independent predictors of HSV-2 infection. CONCLUSION: HSV-2 infection may be occur more often in women who douche, smoke, have sex with uncircumcised partners, or have bacterial vaginosis; these represent alterable risk factors.     

单纯疱疹病毒2型临床分离株体外对阿昔洛韦和伐昔洛韦的敏感性测定

目的 测定南京地区收集的15株单纯疱疹病毒2型(HSV-2)对阿昔洛韦和伐昔洛韦的敏感性,初步建立空斑法提取阿昔洛韦耐药株.方法 Vero细胞培养法分离扩增出临床毒株,直接免疫荧光法分型,并用MTT法测定15株2型毒株对阿昔洛韦、伐昔洛韦的敏感性.体外阿昔洛韦诱导,空斑纯化HSV耐药株.结果 15株临床株对阿昔洛韦和伐昔洛韦的半数病毒抑制质量浓度(IC₅₀)分别为0.0215～0.2799μg/mL(平均0.0766μg/mL),0.0549～0.4575μg/mL(平均0.1605μg/mL).生殖器疱疹初发组与复发组、用药组与未用药组对2种药物的敏感性采用Wilcoxon秩和检验,P值均>0.05,差异无统计学意义.从15株HSV-2临床株中未提取到耐药空斑;从HSV-1 Sam实验室标准株提取到一个耐药空斑,MTT法测定阿昔洛韦IC₅₀为13.36μg/mL;从HSV-2 333标准株中提取到9个耐药空斑,扩增后MTT法测定其对阿昔洛韦的IC₅₀为1.04～5.08 μg/mL.结论 目前在南京地区收集的HSV-2型毒株对阿昔洛韦和伐昔洛韦敏感性较高,尚未发现耐药株.体外药物诱导、空斑纯化能较快提取到HSV耐药株.     

女性原发性生殖器疱疹中HSV-Ⅱ的检测及意义

目的探讨单纯疱疹病毒Ⅱ型(HSV-Ⅱ)与女性原发性生殖器疱疹(GH)的相关性及意义。方法应用酶联免疫吸附法(ELISA)分别检测患者血清中HSV-Ⅱ抗体以及分泌物中的HSV-Ⅱ抗原。结果HSV-Ⅱ中IgG均阴性的138例女性生殖器疱疹患者中HSV-Ⅱ抗原阳性78例(56.52%);HSV-Ⅱ中IgM抗体阳性130例(94.20%),抗体阳性率明显高于抗原阳性率(P<0.01)。典型病例组抗原阳性65例(87.84%),IgM抗体阳性66例(89.19%);不典型病例组抗原阳性13例(20.31%),IgM抗体阳性64例(100.00%)。结论对于皮损时间短,症状典型者可检测HSV-Ⅱ抗原;皮损时间长,或反复者可检测HSV-Ⅱ抗体,可以有效提高HSV感染的临床诊断率。     

Persistence of herpes simplex virus types 1 and 2 in infected individuals.

During a 23-month period, 18 patients with facial or genital herpetic lesions were examined; culture specimens from each patient were obtained three times per week for virologic studies. The isolated viruses were identified, and the average duration of herpesvirus in lesions was determined. Herpes simplex virus type 1 (HSV-1) was isolated from facial lesions for a mean duration of 3 1/2 days. In contrast, herpes simplex virus type 2 (HSV-2) was isolated from genital lesions for a mean duration of 5 1/2 days. The duration of viral persistence in lesions of patients with mild primary infection did not seem to differ from that in patients with recurrent infection.     

生殖器疱疹动物模型的建立及应用

生殖器疱疹主要是由2型人类单纯疱疹病毒引起的性传播疾病.在动物阴道内注射病毒液可以建立生殖器疱疹动物模型,在此基础上还可以进一步建立复发感染模型.利用雌性豚鼠建立生殖器疱疹动物模型对于需要观察皮损变化方面的药效学等研究是较为理想的选择.通过观察豚鼠/小鼠外阴及阴道皮损病变情况并进行评分可以用于生殖器疱疹发病机制的研究,还可以用于抗疱疹病毒新药和疫苗的研究.

Abstract：

Genital herpes is a kind of sexually transmitted disease mainly caused by herpes simplex virus type 2(HSV-2). Injecting virus into the vagina of animals is a common method to establish animal models of genital herpes, which can be used as a basis for the building of recurrent infection models. It is an ideal option to set up animal models of genital herpes by using femal guinea pigs for the observation of drug efficacy in skin lesions. To assess the lesion changes in vulva and vagina of guinea pigs or mice after the inoculation by a scoring method may be used to study the pathogenesis of genital herpes and to develop new antiviral agents and vaccines.     

Detection of varicella zoster virus in genital specimens using a multiplex polymerase chain reaction

OBJECTIVE: To compare the relative proportions of varicella zoster virus (VZV) and herpes simplex viruses in specimens obtained from the genital lesions of adults presenting with presumed genital herpes infection. METHODS: Swabs of genital lesions from 6210 patients attending general practices, infectious diseases clinics within hospitals, or sexual health centres for treatment of their genital lesions were tested using polymerase chain reaction (PCR) technology. The multiplexed PCR was capable of detecting herpes simplex virus types 1 and 2 (HSV-1, HSV-2), VZV, and cytomegalovirus in a single sample. RESULTS: A total of 2225 patients had viruses detected by PCR. HSV-1 was detected in 36%, HSV-2 in 61%, and VZV in 2.9% of PCR positive samples. Of the 65 patients with VZV genital infection, many were thought to have HSV infection before laboratory testing. CONCLUSIONS: The finding of VZV in nearly 3% of virus positive genital specimens demonstrates that this virus needs to be considered as a differential diagnosis for genital herpetic lesions. Advice provided to patients with VZV genital infection regarding the source of infection, likelihood of recurrence, and potential for transmission of the virus will be different from that given to patients with HSV infection.     

Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease

BACKGROUND AND OBJECTIVES: The care of patients with first episode and recurrent genital herpes differs with respect to therapy and source partner evaluation. Of 498 persons who presented with what appeared by history and symptoms to be a first episode of genital herpes, we identified 41 who had serologic evidence of remotely acquired herpes simplex virus 2 (HSV-2) infection. GOALS: To define the natural history of these individuals with previously unrecognized HSV-2 and to evaluate if any clinical or historical features could differentiate these people from persons with true first episode infection. STUDY DESIGN: Observational cohort study. RESULTS: Clinical overlap existed in the frequency of local symptoms, fever, and size of genital lesions between those with remotely acquired versus recently acquired genital herpes. The frequency of new sexual partners and recent sexual history were also similar in the two groups. However, on follow-up, the lesions of persons with remotely acquired HSV-2 healed more rapidly and subsequently recurred less frequently than those of true primary HSV-2. CONCLUSIONS: Even in a referral clinic with experienced clinicians, almost 10% of persons who are judged to have first episode genital herpes have evidence of remotely acquired HSV-2, suggesting that clinical differentiation of first episode genital herpes from previously acquired infection is difficult. Type-specific serologic testing assists the clinician in correctly classifying the infection and determining the potential source partner.     

Evaluation eines dominant-negativen rekombinanten Herpes-simplex-Virus (HSV) Typ 1 als Impfstoff gegen Herpes genitalis bei Mäusen und Meerschweinchen

Genital herpes caused by herpes simplex virus (HSV) is one of the most common sexually transmitted diseases worldwide. Currently, no safe and effective vaccine against HSV is available. CJ9-gD is a completely replication-defective HSV-1 recombinant which inhibits replication of wild-type HSV-1/-2 in co-infected cells (dominant-negative effect). Moreover, it expresses high levels of HSV-1 major antigen glycoprotein D (gD). Immunization with CJ9-gD induces strong and long-lasting humoral and Th1-like cellular immune responses against both HSV-1 and HSV-2 in mice protecting immunized animals significantly against genital challenge with HSV-1 or HSV-2. Guinea pigs immunized with CJ9-gD were significantly protected against primary and recurrent HSV-2 genital disease and latent infection.